

1. In what may be the most important point of all, your office action states that the claims are rejected because they are “narrative in form and replete with indefinite and functional or operational language.” This impression is clearly due to the absence of the technical document, which is replete with specific, unambiguous language about what the invention is and how it may be “built” as an embedded system. For example, see Sections 1 and 2, pages 2–5 in the technical document for explicit details of the OSMMTS. Further details of all aspects of the OSMMTS are stated clearly and definitively throughout the technical document. This point also addresses the comments in your office action that “[t]he structure which goes to make up the device must be clearly and positively specified[.]” and “[t]he structure must be organized and correlated in such a manner as to present a complete operative device.” The technical document presents this information clearly, definitively, and positively.
2. Regarding your comment that Claim 7, line 4 uses the term “i.e.,” which you say means “for example,” I must point out that “i.e.” is an abbreviation for the Latin *id est*, or “that is,” not “for example.” That abbreviation would be “e.g.” for *exempli gratia*. In this regard, the use of “i.e.,” “that is,” in Claim 7 does not render the claim indefinite, rather it is clarifying, therefore definite, and unambiguous.
3. There are several places in your office action where an extraneous “[ ]” is said to be found in the specification. This is evidently an artifact of the electronic submission process, as these “[ ]” marks were not in my original specification. I request that these “informalities” be ignored, or rectified at your end, without further need to alter the specification, since they appear to be an unwanted and unintended “feature” of the ePAVE system in use in 2004.
4. With regard to the specific claims, please accept the following modified Claim 1 that addresses the objections mentioned in your office action. “Claim 1: A method comprising a. the analytical calculation of a target position report for arbitrarily many self-identifying targets in a two-dimensional grid according to Sections 6–10, pages 15–16, of the technical document.”
5. All objections listed in your office action for the wording of Claims 2–8 refer to the use of the word “the” at various places, usually before the word “said.” Please delete all such “the” words from those places in the claims that are listed in your office action. These edits do not change the meaning or clarity of Claims 2–8. In addition, it should be understood that all terms used in the claims have clear and detailed definitions in the technical document.
6. With regard to the rejection of Claim 1 in that it may be “anticipated by Ito (US 6,108,556),” please consider the context of the technical document. Ito (US 6,108,556) contains no such specific, reproducible, clearly

stated, and analytical calculation formula as that found in Sections 6-10, pages 15-16, of the technical document. Even if Ito (US 6,108,556) had contained such a formulation, it did not, and could not, anticipate nor contain *my* formulation — the *OSMMTS* formulation — the OSMMTS analytical calculation method found in the technical document, which is significantly different from, and, I would promote, is superior to, all other such formulations found in the prior art (and my search of the prior art has found no such applicable, specific analytical calculation formula). Such a unique formulation as stated in the technical document serves the purposes of the patent system by enabling an entity to create the OSMMTS system on his own after the patent has expired, independently of any other such implementation, thus promoting competition and innovation.

7. Based on the anticipated acceptance of Claim 1, Claims 2-8 should also be accepted. Your office action stated as much on pages 7-9 under the heading *Allowable Subject Matter*.
8. Finally, the two figures originally submitted in the ePAVE system, which are the ones mentioned on pages 5-6 of your office action, have, once again, been affected by the ePAVE system by the introduction of extraneous characters into the figure names. This is, once again, the source of the "[]" mentioned at the top of page 5 of your office action. Please accept, hopefully once and for all, the two figures (placed separately on the following pages), labeled as replacement sheets, that satisfy all format requirements. Please note that these figures are also used in the technical document, where the referenced characters, such as  $10^{P1}$ ,  $10^{P2}$ , ..., that were mentioned in your office action, are defined and linked to the figures.

Thank you for your time, attention, and help. I truly hope this additional information has answered all your questions and addressed all your objections and observations, and has also made it patently(!) clear that I should be immediately issued letters patent for the OSMMTS.

Sincerely,



Timothy Hall  
PQI Consulting  
P. O. Box 425616  
Cambridge, MA USA 02142-0012  
617-461-5654 / info@pqic.com

Encl: *The OSMMTS Patent Application Technical Documentation*